| 1  | Full-spectrum dynamics of the coronavirus disease outbreak in Wuhan, China: a   |
|----|---|
| 2  | modeling study of 32,583 laboratory-confirmed cases   |
| 3  |   |
| 4  | Short title: Transmission dynamics of COVID-19 in Wuhan   |
| 5  |   |
| 6  | Xingjie Hao <sup>1,2,#</sup> , Shanshan Cheng <sup>1,2,#</sup> , Degang Wu <sup>1,2,#</sup> , Tangchun Wu <sup>1,3,*</sup> , Xihong |
| 7  | Lin <sup>4,*</sup> , Chaolong Wang <sup>1,2,*</sup>   |
| 8  |   |
| 9  | <sup>1</sup> Ministry of Education Key Laboratory of Environment and Health, and State Key  |
| 10 | Laboratory of Environmental Health (Incubating), School of Public Health, Tongji  |
| 11 | Medical College, Huazhong University of Science and Technology, Wuhan, China;   |
| 12 | <sup>2</sup> Department of Epidemiology and Biostatistics, School of Public Health, Tongji  |
| 13 | Medical College, Huazhong University of Science and Technology, Wuhan, China;   |
| 14 | <sup>3</sup> Department of Occupational and Environmental Health, School of Public Health,  |
| 15 | Tongji Medical College, Huazhong University of Science and Technology, Wuhan,   |
| 16 | China.  |
| 17 | <sup>4</sup> Department of Biostatistics, Harvard T.H. Chan School of Public Health, and  |
| 18 | Department of Statistics, Harvard University, Boston, MA, USA;  |
| 19 |   |
| 20 | <sup>#</sup> Co-first authors.  |
| 21 | * Corresponding authors.  |
| 22 |   |
| 23 | Emails: <u>chaolong@hust.edu.cn</u> (C.W.); <u>xlin@hsph.harvard.edu</u> (X.L.);  |
| 24 | wut@tjmu.edu.cn (T.W.)  |
|    |   |

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 1 ABSTRACT

Vigorous non-pharmaceutical interventions have largely suppressed the COVID-19 2 3 outbreak in Wuhan, China. We extended the susceptible-exposed-infectious-recovered model to study the transmission dynamics and evaluate the impact of interventions 4 using 32,583 laboratory-confirmed cases from December 8, 2019 till March 8, 2020, 5 accounting for presymptomatic infectiousness, and time-varying ascertainment rates, 6 transmission rates, and population movements. The effective reproduction number R<sub>0</sub> 7 dropped from 3.54 (95% credible interval: 3.41-3.66) in the early outbreak to 0.27 8 (0.23-0.32) after full-scale multi-pronged interventions. By projection, the 9 interventions reduced the total infections in Wuhan by 96.1% till March 8. Furthermore, 10 we estimated that 87% infections (lower bound: 53%) were unascertained, potentially 11 including asymptomatic and mild-symptomatic cases. The probability of resurgence 12 was 0.33 and 0.06 based on models with 87% and 53% infections unascertained, 13 respectively, assuming all interventions were lifted after 14 days of no ascertained 14 infections. These results provide important implications for continuing surveillance and 15 interventions to eventually contain the outbreak. 16

17

The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was detected in 1 Wuhan, China, in December 2019.<sup>1</sup> Many early cases were connected to the Huanan 2 Seafood Market, which was disinfected on January 1, 2020 to stop potential zoonotic 3 infection.<sup>2</sup> Nevertheless, the high population density of Wuhan together with the 4 increased social activities before the Chinese New Year catalyzed the outbreak in 5 January, 2020. The massive human movement during the holiday travel season 6 Chunyun, which started on January 10, further expedited spreading of the outbreak.<sup>3</sup> 7 8 Shortly after the confirmation of human-to-human transmission, the Chinese authorities implemented the unprecedented cordons sanitaire of Wuhan on January 23 to contain 9 the geographic spread, followed by a series of non-pharmaceutical interventions to 10 reduce virus transmission, including suspension of all intra- and inter-city 11 transportation, compulsory mask wearing in public places, cancelation of social 12 gatherings, and home quarantine of mild-symptomatic patients.<sup>4</sup> From February 2, strict 13 stay-at-home policy for all residents, centralized isolation of all patients, and centralized 14 quarantine of suspected cases and close contacts were implemented to stop household 15 16 and community transmission. Furthermore, a city-wide door-to-door universal symptom survey was carried out during February 17-19 by designated community 17 workers to identify previously undetected symptomatic cases. Details of the 18 interventions were described in Pan et al.<sup>4</sup> These drastic interventions, together with 19 the improved medical resources and healthcare manpower from all over the country, 20 have effectively bent the epidemic curve and reduced the attack rate in Wuhan, 21 shedding light on the global efforts to control the COVID-19 outbreak.<sup>4</sup> 22

23

Recent studies have revealed important transmission features of COVID-19, including infectiousness of asymptomatic cases<sup>5-9</sup> and presymptomatic cases.<sup>10-12</sup> Furthermore, the number of ascertained cases was much smaller than those estimated by earlier modeling-based studies using international cases exported from Wuhan prior to the travel suspension,<sup>3,13,14</sup> implying a substantial number of unascertained cases. Using reported cases from 375 cities in China, a modeling study concluded that substantial

unascertained cases, despite having lower transmissibility, had facilitated the rapid spreading of COVID-19.<sup>15</sup> In addition, accounting for the unascertained cases has refined the estimation of case fatality risk of COVID-19, leading to a better understanding of the clinical severity of the disease.<sup>16</sup> Modeling both ascertained and unascertained cases is important to facilitate interpretation of transmission dynamics and epidemic trajectories.

7

Based on comprehensive epidemiological data from Wuhan,<sup>4</sup> we extended the 8 susceptible-exposed-infectious-recovered (SEIR) model to delineate the full spectrum 9 of COVID-19 outbreak in the epicenter, accounting for presymptomatic infectiousness, 10 unascertained cases, population movement, and different intervention strengths across 11 time periods (Fig. 1). We named the extended model SAPHIRE, because we 12 compartmentalized the population into S susceptible, Ε Ρ 13 exposed, presymptomatic, A unascertained, I ascertained, H isolated, and R removed 14 individuals. Compared with the classic SEIR model, we explicitly modeled population 15 movement<sup>3</sup> and split the infectious cases into P, A, and I to reflect infectiousness at 16 different stages. The unascertained compartment A was expected to mostly consist of 17 asymptomatic and mild-symptomatic cases who were infectious but difficult to detect. 18 We introduced compartment H because ascertained cases would have shorter effective 19 infectious period due to isolation in the hospital, especially when medical resources 20 were improved. 21

22

We chose to model the outbreak from January 1, 2020 and divided it into five time periods based on key events and interventions: January 1 to 9 (before *Chunyun*), January 10 to 22 (*Chunyun*), January 23 to February 1 (*cordons sanitaire*), February 2 to 16 (centralized isolation and quarantine), and February 17 to March 8 (community screening). We assumed a constant population size of 10 million with equal numbers of daily inbound and outbound travelers (500,000 before *Chunyun*, 800,000 during *Chunyun*, and 0 after *cordons sanitaire*).<sup>3</sup> Furthermore, we assumed transmission rate

and ascertainment rate did not change in the first two periods, because few interventions were implemented before January 23, while they were allowed to vary in later periods to reflect different intervention strengths. We used Markov Chain Monte Carlo (MCMC) to estimate these parameters by assuming the daily incidence following a Poisson distribution, while the other parameters were set based on previous epidemiological investigations<sup>2,10</sup> or from our data (**Methods**). We assumed the transmissibility of presymptomatic/unascertained cases to be 0.55 of the ascertained cases.<sup>15,17</sup>

8

9 We first simulated epidemic curves with two periods to test the performance of our parameter estimation procedure (Methods). We converted the transmission rate to the 10 effective reproduction number  $R_0$  and focused on evaluating the estimation of  $R_0$ 11 and the ascertainment rate r in both periods, for which the parameter values were 12 13 different. As shown in Extended Data Figs. 1-2, our method could accurately estimate  $R_0$  and the ascertainment rates when the model was correctly specified and was robust 14 to misspecification of the duration from symptom onset to isolation and the relative 15 16 transmissibility of presymptomatic/unascertained cases to ascertained cases. As expected, estimates of  $R_0$  were positively correlated with the specified latent period 17 and infectious periods, while the estimated ascertainment rates were positively 18 correlated with the specified ascertainment rate in the initial state (Extended Data Fig. 19 2). These simulation results highlighted the importance of carefully specifying 20 parameter values and designing sensitivity analyses based on information from existing 21 22 data and literature.

23

Based on confirmed cases exported from Wuhan to Singapore, we conservatively estimated the ascertainment rate during the early outbreak in Wuhan was 0.23 (95% confidence interval [CI]: 0.14-0.42) (**Methods**). We then applied our model to fit the daily incidences in Wuhan from January 1 to February 29, assuming the initial ascertainment rate was 0.23, and used the fitted model to predict the trend from March 1 to 8. As shown in **Fig. 2A**, our model fit the observed data well, except for the outlier

on February 1, which might be due to approximate-date records of many patients 1 admitted to the field hospitals set up after February 1. After a series of multi-faceted 2 public health interventions, the transmission rate decreased from 1.31 (95% credible 3 interval [CrI]: 1.25-1.37) in the first two periods to 0.40 (0.38-0.42), 0.17 (0.16-0.19), 4 and 0.10 (0.08-0.12) in the later three periods, respectively (Extended Data Table 5), 5 which could be translated into  $R_0$  of 3.54 (3.41-3.66), 3.32 (3.20-3.44), 1.18 (1.11-6 1.25), 0.51 (0.47-0.54) and 0.27 (0.23-0.32) for the five periods, respectively (Fig. 2B, 7 8 **Extended Data Table 6**). We estimated the cumulative number of infections, including unascertained cases, till March 8 to be 257,406 (207,683-315,785) if the trend of the 9 fourth period was assumed (Fig. 2C), or 812,930 (599,992-1,087,944) if the trend of 10 the third period was assumed (Fig. 2D), or 6,302,928 (6,277,193-6,327,431) if the trend 11 of the second period was assumed (Fig. 2E), in comparison to the estimated total 12 infections of 248,022 (199,474-302,464) by fitting data from all five periods (Fig. 2A). 13 These numbers were translated to 3.6%, 69.5%, and 96.1% reduction of infections due 14 to the interventions in different periods. 15

16

Strikingly, we estimated low ascertainment rates across periods, which were 0.15 (0.13-17 0.17) for the first two periods, and 0.14 (0.12-0.17), 0.10 (0.08-0.12), and 0.16 (0.13-18 0.21) for the other three periods, respectively (Extended Data Table 4). Even with the 19 universal community symptom screening implemented on February 17 to 19, the 20 ascertainment rate was only increased to 0.16. Based on the fitted model using data 21 from January 1 to February 29, we projected the cumulative number of ascertained 22 cases to be 32,562 (30,234-34,999) by March 8, close to the actual reported number of 23 24 32,583. This was equivalent to an overall ascertainment rate of 0.13 (0.11-0.16) given the estimated total infections of 248,022 (199,474-302,464). The model also projected 25 that the number of daily active infections in Wuhan, including both ascertained and 26 unascertained, peaked at 55,651 (45,204-67,834) on February 2 and dropped afterwards 27 to 683 (437-1,003) on March 8 (Fig. 2F). If the trend remained unchanged, the number 28 of ascertained infections would first become zero on March 25 (95% CrI: March 18 to 29

April 2), while the clearance of all infections would occur on April 21 (April 8 to May
11), 2020 (Extended Data Table 7). The first day of zero ascertained case in Wuhan
was reported on March 18, which was on the lower 95% CrI of our prediction,
indicating that control measures might have been enhanced in March.

5

The large fraction of unascertained cases has important implications for continuing 6 surveillance and interventions.<sup>18</sup> Based on stochastic simulations, we estimated the 7 probability of resurgence after lifting all controls, assuming the transmission rate, 8 ascertainment rate, and daily population movement were resumed to values of the first 9 period (Methods). Because of the latent, presymptomatic, and unascertained cases, the 10 source of infection would not be completely cleared shortly after the first day of zero 11 ascertained cases. We found that if control measures were lifted 14 days after the first 12 day of zero ascertained cases, despite sparse new cases might be ascertained during the 13 observation period, the probability of resurgence could be as high as 0.97, and the surge 14 was predicted to occur on day 36 (95% CrI: 28-48) after lifting controls (Fig. 3). If we 15 16 were to impose a more stringent criterion of lifting controls after observing no ascertained cases in a consecutive period of 14 days, the probability of resurgence 17 would drop to 0.33, with possible resurgence delayed to day 43 (95% CrI: 34-58) after 18 lifting controls (Fig. 3). These results highlighted the risk of ignoring unascertained 19 cases in switching intervention strategies, despite using an over-simplified model 20 without considering other factors such as imported cases, changes in temperature and 21 humidity, and a stepwise lifting strategy that is currently adopted by Wuhan and other 22 23 cities in China.

24

We performed a series of sensitivity analyses to test the robustness of our results by smoothing the outlier data point on February 1, varying lengths of latent and infectious periods, duration from symptom onset to isolation, ratio of transmissibility of presymptomatic/unascertained cases to ascertained cases, and initial ascertainment rate (Extended Data Tables 4-7, Extended Data Figs. 4-11). Our major findings of

remarkable decrease in  $R_0$  after interventions and the existence of substantial 1 unascertained cases was robust in all sensitivity analyses. Consistent with simulation 2 results, the estimated ascertainment rates were positively correlated with the specified 3 initial ascertainment rate. When we specified the initial ascertainment rate as 0.14 or 4 0.42, the estimated overall ascertainment rate would be 0.08 (0.07-0.10) and 0.23 (0.19-5 0.28), respectively (Extended Data Table 4, Extended Data Figs. 9-10). If we 6 assumed an extreme scenario with no unascertained cases in the early outbreak (model 7 8 S8; Extended Data Fig. 11), the estimated ascertainment rate would be 0.47 (0.38-0.57) overall and 0.58 (0.45-0.73) for the last period, which would represent an upper bound 9 of the ascertainment rate. In this model, because of the higher ascertainment rate 10 compared to the main analysis, we estimated a lower probability of resurgence of 0.06 11 when lifting controls after 14 days of no ascertained cases, and a longer time to 12 resurgence, occurring on day 41 (95% CrI: 31-56) after lifting controls (Fig. 3). We also 13 tested a simplified model assuming complete ascertainment anytime, but this simplified 14 model performed significantly worse than the full model, especially in fitting the rapid 15 16 growth before interventions (Extended Data Fig. 12).

17

Our finding of a large fraction of unascertained cases, despite the strong surveillance in 18 Wuhan, indicated the existence of many asymptomatic or mild-symptomatic but 19 20 infectious cases during the outbreak, highlighting a key challenge to the COVID-19 epidemic control.<sup>19</sup> There is accumulating evidence on the existence of many 21 asymptomatic cases. For example, asymptomatic cases were estimated to account for 22 18% of the infections onboard the Diamond Princess Cruise ship<sup>7</sup> and 31% of the 23 infected Japanese evacuated from Wuhan.<sup>8</sup> In addition, it was reported that 29 of the 33 24 (88%) infected pregnant women were asymptomatic by universal screening of 210 25 women admitted for delivery between March 22 and April 4 in New York City.<sup>9</sup> Several 26 reports also highlighted the difficulty in detecting COVID-19 cases: about two thirds 27 of the cases exported from mainland China remained undetected worldwide,<sup>20</sup> and the 28 29 detection capacity varied from 11% in low surveillance countries to 40% in high

surveillance countries.<sup>21,22</sup> By modeling the epidemics in other cities, it was also 1 estimated that the ascertainment rate of infected individuals was about 24.4% in China 2 (excluding Hubei province)<sup>14</sup> and 14% in Wuhan prior to travel ban.<sup>15</sup> Consistent with 3 these studies, our extensive analyses of the most comprehensive epidemic data from 4 Wuhan also indicated an overall ascertainment rate between 7% and 28% (Extended 5 Data Table 4, excluding the extreme scenario of model S8). These results were also 6 consistent with emerging serological studies, showing much higher seroprevalence than 7 the reported case prevalence in different regions of the world.<sup>23,24</sup> The large fraction of 8 unascertained cases would lead to about one month delay between the first occurrence 9 of no ascertained cases and the clearance of all infections (Extended Data Table 6), 10 imposing a high risk of resurgence after lifting controls (Fig. 3). Therefore, 11 understanding the proportion of unascertained cases and the asymptomatic 12 transmissibility will be critical for prioritization of the surveillance and control 13 measures.<sup>18,25</sup> Currently, Wuhan is implementing a strategy to normalize and restore 14 societal activities gradually while maintaining strong disease surveillance. The 15 16 experience and outcome of Wuhan will be valuable to other countries who will eventually face the same issue. 17

18

In the absence of interventions,  $R_0$  is the basic reproduction number, which is a key 19 measurement of the virus transmissibility. We noted that our  $R_0$  estimate of 3.54 (3.41-20 3.66) before any interventions was at the higher end of the range of  $R_0$  estimated by 21 other studies using early epidemic data from Wuhan (1.40-6.49 with a median of 22 2.79).<sup>2,14,15,26-28</sup> Several plausible reasons might explain the discrepancy, including 23 potential impact of unascertained cases, more complete case records in our analysis, 24 and different time periods analyzed. If we considered a model starting from the first 25 COVID-19 case reported in Wuhan (Extended Data Fig. 13), from which we estimated 26 a lower  $R_0$  of 3.38 (3.28-3.48) before January 23, 2020, similar to the value of 3.15 27 reported by a recent study.<sup>27</sup> Nevertheless, this reproduction number was still much 28 higher than the earlier estimates and those for SARS and MERS,<sup>29,30</sup> featuring another 29

1 challenge to control the spread of COVID-19.

2

Taken together, our modeling study delineated the full-spectrum dynamics of the 3 COVID-19 outbreak in Wuhan, and highlighted two key features of the outbreak: a high 4 proportion of asymptomatic or mild-symptomatic cases who were difficult to detect, 5 and high transmissibility. These two features synergistically propelled the global 6 pandemic of COVID-19, imposing grand challenges to control the outbreak. 7 8 Nevertheless, lessons from Wuhan have demonstrated that vigorous and multifaceted containment efforts can considerably control the size of the outbreak, as evidenced by 9 the remarkable decrease of  $R_0$  from 3.54 to 0.27 and an estimated 96.1% reduction of 10 infections till March 8. These are important information for other countries combatting 11 the outbreak. 12

13

Some limitations of our study should be noted. First, we need field investigations and 14 serologic studies to confirm our estimate of the ascertainment rate, and the 15 16 generalizability to other places is unknown. This may depend on the detection capacity in different locations.<sup>22</sup> Second, due to the delay in laboratory tests, we might have 17 missed some cases and therefore underestimated the ascertainment rate, especially for 18 the last period. Third, we excluded clinically diagnosed cases without laboratory 19 confirmation to reduce false positive diagnoses, which, however, would lead to lower 20 estimates of ascertainment rates, especially for the third and fourth periods when many 21 clinically diagnosed cases were reported.<sup>4</sup> The variation in the estimated ascertainment 22 rates across periods reflected a combined effect of the evolving surveillance, 23 interventions, medical resources, and case definitions across time periods.<sup>4,31</sup> Fourth, 24 our model assumed homogeneous transmission within the population while ignoring 25 heterogeneity between groups by sex, age, geographic regions and socioeconomic 26 status. Furthermore, individual variation in infectiousness, such as superspreading 27 events,<sup>32</sup> is known to result in a higher probability of stochastic extinction given a fixed 28 population  $R_0$ .<sup>33</sup> Therefore, we might have overestimated the probability of resurgence. 29

Finally, we could not evaluate the impact of individual interventions based on the 1 epidemic curve from a single city, because many interventions were applied 2 3 simultaneously. Future work by modeling heterogeneous transmission between different groups and joint analysis with data from other cities will lead to deeper insights 4 on the effectiveness of different control strategies.<sup>27,34</sup> 5 6 Data and codes availability 7 R codes and data are available at http://chaolongwang.github.io/codes covid19.zip. 8 9 Acknowledgements: We thank Dr. Huaiyu Tian from Beijing Normal University and 10 the anonymous reviewers for constructive comments. This study was partly supported 11 by the Fundamental Research Funds for the Central Universities (2019kfyXMBZ015), 12 13 the 111 Project (X.H., S.C., D.W., C.W., T.W.). X.L. is supported by Harvard University. 14 Author contributions: TW, XL and CW designed the study. XH, SC, XL and CW 15 16 developed statistical methods. XH, SC, and DW performed data analysis. CW wrote the first draft of the manuscript. All authors reviewed and edited the manuscript. 17 18 19 **Competing interests:** The authors declare no competing interests. 20 REFERENCES 21 22 1 World Health Organization. Coronavirus disease 2019 (COVID-19) situation report-76. 23 (2020). 24 2 Li, Q. et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected 25 Pneumonia. N Engl J Med 382, 1199-1207, doi:10.1056/NEJMoa2001316 (2020). 26 3 Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic 27 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 28 modelling study. Lancet (London, England) 395, 689-697, doi:10.1016/S0140-29 6736(20)30260-9 (2020). 30 4 Pan, A. et al. Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. JAMA, doi:10.1001/jama.2020.6130 (2020). 31 32 5 Bai, Y. et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA, 33 doi:10.1001/jama.2020.2565 (2020). 34 Hoehl, S. et al. Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, 6

| 1  |    | China. <i>N Engl J Med</i> <b>382</b> , 1278-1280, doi:10.1056/NEJMc2001899 (2020).                |
|----|----|--|
| 2  | 7  | Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic                   |
| 3  |    | proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess              |
| 4  |    | cruise ship, Yokohama, Japan, 2020. <i>Euro Surveill</i> <b>25</b> , doi:10.2807/1560-             |
| 5  |    | 7917.ES.2020.25.10.2000180 (2020).   |
| 6  | 8  | Nishiura, H. et al. Estimation of the asymptomatic ratio of novel coronavirus infections           |
| 7  |    | (COVID-19). Int J Infect Dis 94, 154-155, doi:10.1016/j.ijid.2020.03.020 (2020).                   |
| 8  | 9  | Sutton, D., Fuchs, K., D'Alton, M. & Goffman, D. Universal Screening for SARS-CoV-2 in             |
| 9  |    | Women Admitted for Delivery. N Engl J Med, doi:10.1056/NEJMc2009316 (2020).                        |
| 10 | 10 | He, X. et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat            |
| 11 |    | Med 26, 672-675, doi:10.1038/s41591-020-0869-5 (2020).   |
| 12 | 11 | Tong, Z. D. et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang                   |
| 13 |    | Province, China, 2020. Emerg Infect Dis 26, 1052-1054, doi:10.3201/eid2605.200198                  |
| 14 |    | (2020).  |
| 15 | 12 | Ferretti, L. et al. Quantifying SARS-CoV-2 transmission suggests epidemic control with             |
| 16 |    | digital contact tracing. Science 368, doi:10.1126/science.abb6936 (2020).                          |
| 17 | 13 | Kucharski, A. J. et al. Early dynamics of transmission and control of COVID-19: a                  |
| 18 |    | mathematical modelling study. Lancet Infect Dis 20, 553-558, doi:10.1016/S1473-                    |
| 19 |    | 3099(20)30144-4 (2020).  |
| 20 | 14 | Chinazzi, M. et al. The effect of travel restrictions on the spread of the 2019 novel              |
| 21 |    | coronavirus (COVID-19) outbreak. Science 368, 395-400, doi:10.1126/science.aba9757                 |
| 22 |    | (2020).  |
| 23 | 15 | Li, R. et al. Substantial undocumented infection facilitates the rapid dissemination of novel      |
| 24 |    | coronavirus (SARS-CoV-2). <i>Science</i> <b>368</b> , 489-493, doi:10.1126/science.abb3221 (2020). |
| 25 | 16 | Wu, J. T. et al. Estimating clinical severity of COVID-19 from the transmission dynamics in        |
| 26 |    | Wuhan, China. <i>Nat Med</i> <b>26</b> , 506-510, doi:10.1038/s41591-020-0822-7 (2020).            |
| 27 | 17 | Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis,             |
| 28 |    | doi:10.1016/S1473-3099(20)30232-2 (2020).  |
| 29 | 18 | Lipsitch, M., Swerdlow, D. L. & Finelli, L. Defining the Epidemiology of Covid-19 - Studies        |
| 30 |    | Needed. N Engl J Med <b>382</b> , 1194-1196, doi:10.1056/NEJMp2002125 (2020).                      |
| 31 | 19 | Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D. & de Wit, E. A Novel                 |
| 32 |    | Coronavirus Emerging in China - Key Questions for Impact Assessment. N Engl J Med 382,             |
| 33 |    | 692-694, doi:10.1056/NEJMp2000929 (2020).  |
| 34 | 20 | Bhatia, S. et al. Report 6: Relative sensitivity of international surveillance (2020).             |
| 35 | 21 | De Salazar, P. M., Niehus, R., Taylor, A., Buckee, C. O. & Lipsitch, M. Using predicted            |
| 36 |    | imports of 2019-nCoV cases to determine locations that may not be identifying all                  |
| 37 |    | imported cases. <i>medRxiv</i> , doi:10.1101/2020.02.04.20020495 (2020).                           |
| 38 | 22 | Niehus, R., De Salazar, P. M., Taylor, A. & Lipsitch, M. Quantifying bias of COVID-19              |
| 39 |    | prevalence and severity estimates in Wuhan, China that depend on reported cases in                 |
| 40 |    | international travelers. <i>medRxiv</i> , doi:10.1101/2020.02.13.20022707 (2020).                  |
| 41 | 23 | Bendavid, E. et al. COVID-19 antibody seroprevalence in Santa Clara county, California.            |
| 42 |    | <i>medRxiv</i> , doi:10.1101/2020.04.14.20062463 (2020).   |
| 43 | 24 | Levesque, J. & Maybury, D. W. A note on COVID-19 seroprevalence studies: a meta-                   |
| 44 |    | analysis using hierarchical modelling. <i>medRxiv</i> , doi:10.1101/2020.05.03.20089201 (2020).    |

| 1  | 25 | Morens, D. M., Daszak, P. & Taubenberger, J. K. Escaping Pandora's Box - Another Novel                  |  |  |  |  |  |  |
|----|----|---|--|--|--|--|--|--|
| 2  |    | Coronavirus. <i>N Engl J Med</i> <b>382</b> , 1293-1295, doi:10.1056/NEJMp2002106 (2020).               |  |  |  |  |  |  |
| 3  | 26 | Liu, Y., Gayle, A. A., Wilder-Smith, A. & Rocklov, J. The reproductive number of COVID-19               |  |  |  |  |  |  |
| 4  |    | is higher compared to SARS coronavirus. <i>J Travel Med</i> , doi:10.1093/jtm/taaa021 (2020).           |  |  |  |  |  |  |
| 5  | 27 | Tian, H. et al. An investigation of transmission control measures during the first 50 days              |  |  |  |  |  |  |
| 6  |    | of the COVID-19 epidemic in China. Science 368, 638-642, doi:10.1126/science.abb6105                    |  |  |  |  |  |  |
| 7  |    | (2020).   |  |  |  |  |  |  |
| 8  | 28 | Chen, T. M. et al. A mathematical model for simulating the phase-based transmissibility                 |  |  |  |  |  |  |
| 9  |    | of a novel coronavirus. <i>Infect Dis Poverty</i> <b>9</b> , 24, doi:10.1186/s40249-020-00640-3 (2020). |  |  |  |  |  |  |
| 10 | 29 | Wang, Y., Wang, Y., Chen, Y. & Qin, Q. Unique epidemiological and clinical features of the              |  |  |  |  |  |  |
| 11 |    | emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control                          |  |  |  |  |  |  |
| 12 |    | measures. <i>J Med Virol</i> , doi:10.1002/jmv.25748 (2020).  |  |  |  |  |  |  |
| 13 | 30 | Lipsitch, M. et al. Transmission dynamics and control of severe acute respiratory syndrome.             |  |  |  |  |  |  |
| 14 |    | <i>Science</i> <b>300</b> , 1966-1970, doi:10.1126/science.1086616 (2003).                              |  |  |  |  |  |  |
| 15 | 31 | Tsang, T. K. et al. Effect of changing case definitions for COVID-19 on the epidemic curve              |  |  |  |  |  |  |
| 16 |    | and transmission parameters in mainland China: a modelling study. Lancet Public Health                  |  |  |  |  |  |  |
| 17 |    | <b>5</b> , e289-e296, doi:10.1016/S2468-2667(20)30089-X (2020).   |  |  |  |  |  |  |
| 18 | 32 | Liu, Y., Eggo, R. M. & Kucharski, A. J. Secondary attack rate and superspreading events for             |  |  |  |  |  |  |
| 19 |    | SARS-CoV-2. Lancet (London, England) 395, e47, doi:10.1016/S0140-6736(20)30462-1                        |  |  |  |  |  |  |
| 20 |    | (2020).   |  |  |  |  |  |  |
| 21 | 33 | Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the effect           |  |  |  |  |  |  |
| 22 |    | of individual variation on disease emergence. <i>Nature</i> <b>438</b> , 355-359,                       |  |  |  |  |  |  |
| 23 |    | doi:10.1038/nature04153 (2005).   |  |  |  |  |  |  |
| 24 | 34 | Prem, K. et al. The effect of control strategies to reduce social mixing on outcomes of the             |  |  |  |  |  |  |
| 25 |    | COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health 5, e261-                     |  |  |  |  |  |  |
| 26 |    | e270, doi:10.1016/S2468-2667(20)30073-6 (2020).   |  |  |  |  |  |  |
| 27 | 35 | Haario, H., Laine, M., Mira, A. & Saksman, E. DRAM: Efficient adaptive MCMC. Statistics                 |  |  |  |  |  |  |
| 28 |    | and Computing 16, 339-354, doi:10.1007/s11222-006-9438-0 (2006).  |  |  |  |  |  |  |
| 29 | 36 | Brooks, S. P. & Gelman, A. General methods for monitoring convergence of iterative                      |  |  |  |  |  |  |
| 30 |    | simulations. <i>J Comput Graph Stat</i> <b>7</b> , 434-455 (1997).                                      |  |  |  |  |  |  |
| 31 |    |   |  |  |  |  |  |  |



1

2 Fig. 1. Illustration of the SAPHIRE model. We extended the classic SEIR model to 3 include seven compartments, namely S (susceptible), E (exposed), P (presymptomatic infectious), I (ascertained infectious), A (unascertained infectious), H (isolated), and R 4 (removed). (A) Relationship between different compartments in the model. Two 5 parameters of interests are r (ascertainment rate) and b (transmission rate), which are 6 assumed to be varying across time periods. (B) Schematic timeline of an individual 7 from being exposed to the virus to recovery without isolation. In this model, the 8 unascertained compartment A includes asymptomatic and some mild-symptomatic 9 cases who were not detected. While there is no presymptomatic phase for asymptomatic 10 cases, we treated asymptomatic as a special case of mild-symptomatic and modeled 11 both with a "presymptomatic" phase for simplicity. 12



1

2 Fig. 2. Modeling the COVID-19 epidemic in Wuhan. Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 3 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in 4 5 parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 6 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-7 22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active 8 infectious cases in Wuhan from January 1 to March 8. 9



2 Fig. 3. Risk of resurgence after lifting controls. We considered the main model (M) and the sensitivity analysis model S8 (see Methods). In model M, we assumed the 3 initial ascertainment rate  $r_0 = 0.23$ , and thus had a 0.13 estimate of the overall 4 ascertainment rate. In model S8, we assumed no unascertained cases in the initial state 5 6 and thus had a 0.46 estimate of the overall ascertainment rate. For each model, we simulated epidemic curves based on 10,000 sets of parameter values from MCMC, 7 8 assuming transmission rate b, ascertainment rate r, and population movement nwere resumed to values before *Chunyun* after lifting controls. A resurgence was defined 9 by when the number of active ascertained infections raised to over 100. (A) Illustration 10 of a simulated curve under the main model with control measures lifted 14 days after 11 the first day of no ascertained cases. The inserted panel is a zoom-in plot from March 12 16 to May 28. (B) Probability of resurgence if control measures were lifted t days 13

1

after the first observation of no ascertained cases, or after observing zero ascertained cases in a consecutive period of t days. (C) Expectation of time to resurgence conditional on the occurrence of resurgence. We grouped the last 10 days (t = 21 to 30) to calculate the expected time to resurgence because of their low probability of resurgence.

## 1 Methods

## 2 Data of COVID-19 cases in Wuhan

Detailed description of the data can be found in Pan *et al.*<sup>4</sup> Briefly, information of COVID-19 cases from December 8, 2019 till March 8, 2020 were extracted from the municipal Notifiable Disease Report System on March 9, 2020. Date of symptom onset (the self-reported date of symptoms such as fever, cough, or other respiratory symptoms) and date of confirmed diagnosis were collected for each case. For the consistency of case definition throughout the periods, we only included 32,583 laboratory-confirmed cases who were tested positive for SARS-CoV-2 by the real-time reverse-transcription-polymerasechain-reaction (RT-PCR) assay or high-throughput sequencing of nasal and pharyngeal swab specimens.

10

### 11 Estimation of ascertainment rate using cases exported to Singapore

12 As of May 10, 2020, a total of 24 confirmed COVID-19 cases in Singapore were reported to import from 13 China, among which 16 were imported from Wuhan before the cordons sanitaire on January 23 14 (Extended Data Table 1). Based on VariFlight Data (<u>https://data.variflight.com/en/</u>), the total number 15 of passengers from Wuhan to Singapore between January 18 and 23, 2020 was 2,722. Therefore, the 16 cumulative infection rate among the passengers was 0.59% (=16/2722, 95% CI: 0.30-0.88%). These 17 cases had symptom onset from January 21 to 30, 2020. In Wuhan, a total of 12,433 confirmed cases were 18 reported to have symptom onset in the same period, equivalent to a cumulative infection rate of 0.124% 19 (95% CI: 0.122–0.126%) by assuming a population size of 10 million for Wuhan. By further assuming 20 complete ascertainment of early cases in Singapore, which is well known for excellent surveillance 21 strength,<sup>21,22</sup> the ascertainment rate in Wuhan was estimated to be 0.23 (95% CI: 0.14-0.42), 22 corresponding to 0.77 (95% CI: 0.58-0.86) of the infections being unascertained during the early outbreak 23 in Wuhan. This represents a conservative estimate for two reasons: (1) the assumption of perfect ascertainment in Singapore ignored potential asymptomatic cases;<sup>7,8</sup> and (2) the number of imported 24 25 cases with onset between January 21 and 30 was censored due to suspension of flights after Wuhan 26 lockdown. We used these results to set the initial value and the prior distribution of ascertainment rates 27 in our model.

28

#### 29 The SAPHIRE model

30 We extended the classic susceptible-exposed-infectious-recovered (SEIR) model to a SAPHIRE model

1 (Fig. 1), which incorporates three additional compartments to account for presymptomatic infectiousness 2 (P), unascertained cases (A), and case isolation in the hospital (H). We chose to analyze data from January 3 1, 2020, when the Huanan Seafood Market was disinfected, and thus did not model the zoonotic force of 4 infection. We assumed a constant population size N = 10,000,000 with equal number of daily inbound 5 and outbound travelers n, where n = 500,000 for January 1-9, 800,000 for January 10-22 due to 6 Chunyun, and 0 after cordons sanitaire from January  $23.^3$  We divided the population into S susceptible, 7 E exposed, P presymptomatic infectious, A unascertained infectious, I ascertained infectious, H 8 isolated, and R removed individuals. Dynamics of these seven compartments across time t were 9 described by the following set of ordinary differential equations:

10 
$$\frac{\mathrm{d}s}{\mathrm{d}t} = n - \frac{bS(\alpha P + \alpha A + I)}{N} - \frac{nS}{N} \tag{1}$$

11 
$$\frac{dE}{dt} = \frac{bS(\alpha P + \alpha A + I)}{N} - \frac{E}{D_e} - \frac{nE}{N}$$
(2)

12 
$$\frac{\mathrm{d}P}{\mathrm{d}t} = \frac{E}{D_e} - \frac{P}{D_p} - \frac{nP}{N}$$
(3)

13 
$$\frac{\mathrm{d}A}{\mathrm{d}t} = \frac{(1-r)P}{D_p} - \frac{A}{D_i} - \frac{nA}{N} \tag{4}$$

14 
$$\frac{\mathrm{d}I}{\mathrm{d}t} = \frac{rP}{D_p} - \frac{I}{D_i} - \frac{I}{D_q} \tag{5}$$

15 
$$\frac{\mathrm{d}H}{\mathrm{d}t} = \frac{I}{D_q} - \frac{H}{D_h} \tag{6}$$

16 
$$\frac{\mathrm{d}R}{\mathrm{d}t} = \frac{A+I}{D_i} + \frac{H}{D_h} - \frac{nR}{N} \tag{7}$$

17 where *b* was the transmission rate, defined as the number of individuals that an ascertained case can 18 infect per day;  $\alpha$  was the ratio of the transmission rate of presymptomatic/unascertained over 19 ascertained cases; *r* was ascertainment rate;  $D_e$  was the latent period;  $D_p$  was the presymptomatic 20 infectious period;  $D_i$  was the symptomatic infectious period;  $D_q$  was the duration from illness onset to 21 isolation; and  $D_h$  was the isolation period in hospital. The effective reproduction number  $R_0$  could be 22 computed as

$$R_0 = \alpha b \left( D_p^{-1} + \frac{n}{N} \right)^{-1} + (1 - r)\alpha b \left( D_i^{-1} + \frac{n}{N} \right)^{-1} + r b \left( D_i^{-1} + D_q^{-1} \right)^{-1}$$
(8)

where the three terms represent infections contributed by presymptomatic, unascertained, and ascertained cases, respectively. We adjusted the infectious periods of each type of cases by taking population movement  $\left(\frac{n}{N}\right)$  and isolation  $\left(D_q^{-1}\right)$  into account.

23

#### 1

## 2 Parameter settings and initial states

3 Parameter settings for the main analysis were summarized in Extended Data Table 2. We set  $\alpha = 0.55$ according to Li et al.<sup>15</sup>, assuming lower transmissibility for presymptomatic and unascertained cases. We 4 5 assumed an incubation period of 5.2 days and a presymptomatic infectious period of  $D_p = 2.3$  days.<sup>2,10</sup> Thus the latent period was  $D_e = 5.2 - 2.3 = 2.9$  days. Because presymptomatic infectiousness was 6 estimated to account for 44% of the total infections of ascertained cases,<sup>10</sup> we set the total infectious 7 period as  $(D_p + D_i) = \frac{D_p}{0.44} = 5.2$  days, thus the symptomatic infectious period was  $D_i = 2.9$  days. We 8 9 set a long isolation period of  $D_h = 30$  days, but this parameter has no impact on our fitting procedure 10 and the final parameter estimates. The duration from symptom onset to isolation was estimated to be 11  $D_q = 21, 15, 10, 6, and 2$  days as the median time length from onset to confirmed diagnosis in each 12 period, respectively.

13 Based on the settings above, we specified the initial state of the model on December 31, 2019 14 (Extended Data Table 3). The initial number of ascertained symptomatic cases I(0) was specified as 15 the number of ascertained cases with onset during December 29-31, 2019. We assumed the initial 16 ascertainment rate was  $r_0$ , and thus the initial number of unascertained cases was A(0) =17  $r_0^{-1}(1-r_0)I(0)$ . We denoted  $P_I(0)$  and  $E_I(0)$  as the numbers of ascertained cases with onset during 18 January 1-2, 2020 and during January 3-5, 2020, respectively. Then, the initial numbers of exposed cases and presymptomatic cases were set as  $E(0) = r_0^{-1} E_I(0)$  and  $P(0) = r_0^{-1} P_I(0)$ , respectively. We 19 20 assumed  $r_0 = 0.23$  in our main analysis based on the point estimate using the Singapore data (described 21 above).

22

## 23 Estimation of parameters in the SEIR model

Considering the time-varying strength of control measures, we assumed  $b = b_{12}$  and  $r = r_{12}$  for the first two periods,  $b = b_3$  and  $r = r_3$  for period 3,  $b = b_4$  and  $r = r_4$  for period 4, and  $b = b_5$  and  $r = r_5$  for period 5. We assumed the observed number of ascertained cases with symptom onset on day d, denoted as  $x_d$ , followed a Poisson distribution with rate  $\lambda_d = rP_{d-1}D_p^{-1}$ , where  $P_{d-1}$  was the expected number of presymptomatic cases on day (d-1). We fit the observed data from January 1 to February 29 (d = 1, 2, ..., D, and D = 60) and used the fitted model to predict the trend from March 1

1 to 8. Thus, the likelihood function was

$$L(b_{12}, b_3, b_4, b_5, r_{12}, r_3, r_4, r_5) = \prod_{d=1}^{D} \frac{e^{-\lambda_d} \lambda_d^{\chi_d}}{x_d!}.$$
(9)

We estimated  $b_{12}$ ,  $b_3$ ,  $b_4$ ,  $b_5$   $r_{12}$ ,  $r_3$ ,  $r_4$ , and  $r_5$  by Markov Chain Monte Carlo (MCMC) with the Delayed Rejection Adaptive Metropolis (DRAM) algorithm implemented in the R package *BayesianTools* (version 0.1.7).<sup>35</sup> We used a non-informative flat prior of Uinf(0, 2) for  $b_{12}$ ,  $b_3$ ,  $b_4$ , and  $b_5$ . For  $r_{12}$ , we used an informative prior of Beta(7.3, 24.6) by matching the first two moments of the estimate using Singapore data (described above). We reparameterized  $r_3$ ,  $r_4$ , and  $r_5$  by

- 8  $\operatorname{logit}(r_3) = \operatorname{logit}(r_{12}) + \delta_3$
- 9  $\operatorname{logit}(r_4) = \operatorname{logit}(r_3) + \delta_4$
- 10  $\operatorname{logit}(r_5) = \operatorname{logit}(r_4) + \delta_5$

11 where  $logit(r) = log(\frac{r}{1-r})$ . In the MCMC, we sampled  $\delta_3$ ,  $\delta_4$ , and  $\delta_5$  from the prior of N(0, 1). We 12 set a burn-in period of 40,000 iterations and continued to run 100,000 iterations with a sampling step size 13 of 10 iterations. We repeated MCMC with three different sets of initial values and assessed the 14 convergence by the trace plot and the multivariate Gelman-Rubin diagnostic (**Extended Data Fig. 3**).<sup>36</sup> 15 Estimates of parameters were presented as posterior means and 95% credible intervals (CrIs) from 10,000 16 MCMC samples. All the analyses were performed in R (version 3.6.2) and the Gelman-Rubin diagnostic 17 was calculated using the *gelman.diag* function in the R package *coda*.

18

2

#### 19 Stochastic simulations

20 We used stochastic simulations to obtain 95% CrI of fitted/predicted epidemic curve. Given a set of

21 parameter values from MCMC, we performed the following multinomial random sampling:

22 
$$(U_{S \to E}, U_{S \to 0}, U_{S \to S}) \sim \text{Multinomial}(S_{t-1}; p_{S \to E}, p_0, 1 - p_{S \to E} - p_0)$$

23 
$$(U_{E \to P}, U_{E \to O}, U_{E \to E}) \sim \text{Multinomial}(E_{t-1}; p_{E \to P}, p_0, 1 - p_{E \to P} - p_0)$$

24 
$$(U_{P \to I}, U_{P \to A}, U_{P \to O}, U_{P \to P})$$
 ~ Multinomial  $(P_{t-1}; p_{P \to I}, p_{P \to A}, p_0, 1 - p_{P \to I} - p_{P \to A} - p_0)$ 

25 
$$(U_{I \to H}, U_{I \to R}, U_{I \to I})$$
 ~ Multinomial $(I_{t-1}; p_{I \to H}, p_{I \to R}, 1 - p_{I \to H} - p_{I \to R})$ 

26 
$$(U_{A \to R}, U_{A \to 0}, U_{A \to A}) \sim \text{Multinomial}(A_{t-1}; p_{A \to R}, p_0, 1 - p_{A \to R} - p_0)$$

27 
$$(U_{H \to R}, U_{H \to H}) \sim \text{Multinomial}(H_{t-1}; p_{H \to R}, 1 - p_{H \to R})$$

28 
$$(U_{R \to 0}, U_{R \to R}) \sim \text{Multinomial}(R_{t-1}; p_0, 1 - p_0)$$

29 where O denotes the status of outflow population,  $p_0 = nN^{-1}$  denotes the outflow probability, and

| 1  | other quantities are status transition probabilities, including $p_{S \to E} = b(\alpha P_{t-1} + \alpha A_{t-1} + I_{t-1})$   | $)N^{-1}$ ,    |
|----|--|----------------|
| 2  | $p_{E \to P} = D_e^{-1}, \ p_{P \to I} = r D_p^{-1}, \ p_{P \to A} = (1 - r) D_p^{-1}, \ p_{I \to H} = D_q^{-1}, \ p_{I \to R} = p_{A \to R} = D_i^{-1}, \ \text{and} \ p_{I \to R} = p_{A \to R} = D_i^{-1}, \ p_{I \to R}$ | $_{H \to R} =$ |
| 3  | $D_h^{-1}$ . The SAPHIRE model described by Eqs. 1-7 is equivalent to the following stochastic dynam   | ics:           |
| 4  | $S_t - S_{t-1} = n - U_{S \to E} - U_{S \to 0}$  | (10)           |
| 5  | $E_t - E_{t-1} = U_{S \to E} - U_{E \to P} - U_{E \to O}$  | (11)           |
| 6  | $P_t - P_{t-1} = U_{E \to P} - U_{P \to A} - U_{P \to I} - U_{P \to O}$  | (12)           |
| 7  | $A_t - A_{t-1} = U_{P \to A} - U_{A \to R} - U_{A \to O}$  | (13)           |
| 8  | $I_t - I_{t-1} = U_{P \to I} - U_{I \to H} - U_{I \to R}$  | (14)           |
| 9  | $H_t - H_{t-1} = U_{I \to H} - U_{H \to R}$  | (15)           |
| 10 | $R_t - R_{t-1} = U_{A \to R} + U_{I \to R} + U_{H \to R} - U_{R \to O}.$   | (16)           |
| 11 | We repeated the stochastic simulations for all 10,000 sets of parameter values sampled by MC   | MC to          |
| 12 | construct the 95% CrI of the epidemic curve by the 2.5 and 97.5 percentiles at each time point.  |                |

13

#### 14 Prediction of epidemic ending date and the risk of resurgence

15 Using the stochastic simulations described above, we predicted the first day of no new ascertained cases 16 and the date of clearance of all active infections in Wuhan, assuming continuation of the same control 17 measures as the last period (*i.e.*, same parameter values).

18 We also evaluated the risk of outbreak resurgence after lifting control measures. We considered 19 lifting all controls (1) at t days after the first day of zero ascertained cases, or (2) after a consecutive 20 period of t days with no ascertained cases. After lifting controls, we set the transmission rate b, 21 ascertainment rate r, and population movement n to be the same as the first period, and continued the 22 stochastic simulation to stationary state. Time to resurgence was defined as the number of days from 23 lifting controls to when the number of ascertained cases I reached 100. We performed 10,000 24 simulations with 10,000 sets of parameter values sampled from MCMC (as described above). We 25 calculated the probability of resurgence as the proportion of simulations in which a resurgence occurred, 26 as well as the time to resurgence conditional on the occurrence of resurgence.

27

#### 28 Simulation study for method validation

29 To validate our method, we performed two-period stochastic simulations (Eqs. 10-16) with transmission

1 rate  $b = b_1 = 1.27$ , ascertainment rate  $r = r_1 = 0.2$ , daily population movement n = 500,000, and 2 duration from illness onset to isolation  $D_q = 20$  days for the first period (so that  $R_0 = 3.5$  according to Eq. 8), and  $b = b_2 = 0.41$ ,  $r = r_2 = 0.4$ , n = 0, and  $D_q = 5$  for the second period (so that  $R_0 = 0.4$ ) 3 4 1.2 according to Eq. 8). Lengths of both periods were set to 15 days, and the initial ascertainment rate 5 was set to  $r_0 = 0.3$ , while the other parameters and initial states were set as those in our main analysis 6 (Extended Data Tables 2-3). We repeated stochastic simulations 100 times to generate 100 datasets. For 7 each dataset, we applied our MCMC method to estimate  $b_1$ ,  $b_2$ ,  $r_1$  and  $r_2$ , while setting all other 8 parameters and initial values the same as the true values. We translated  $b_1$  and  $b_2$  into  $(R_0)_1$  and 9  $(R_0)_2$  according to Eq. 8, and focused on evaluating the estimates of  $(R_0)_1$ ,  $(R_0)_2$ ,  $r_1$  and  $r_2$ . We also 10 tested the robustness to misspecification of the latent period  $D_e$ , presymptomatic infectious period  $D_p$ , 11 symptomatic infectious period  $D_i$ , duration from illness onset to isolation  $D_q$ , ratio of transmissibility 12 between unascertained/presymptomatic cases and ascertained cases  $\alpha$ , and initial ascertainment rate  $r_0$ . 13 In each test, we changed the specified value of a parameter (or initial state) to be 20% lower or higher than its true value, while keeping all other parameters unchanged. When we changed the value of  $r_0$ , we 14 15 adjusted the initial states A(0), P(0), and E(0) according to Extended Data Table 3.

For each simulated dataset, we ran the MCMC method with 20,000 burn-in iterations and an additional 30,000 iterations. We sampled parameter values from every 10 iterations, resulting in 3,000 MCMC samples. We took the mean across 3,000 MCMC samples as the final estimates and displayed results for 100 repeated simulations using boxplots.

20

### 21 Sensitivity analyses for the real data

We designed nine sensitivity analyses to test the robustness of our real data results. For each of the sensitivity analyses, we fixed parameters and initial states to be the same as the main analysis except for those mentioned below.

(S1) Adjust the reported incidences from January 29 to February 1 to their average. We suspect the spike
 of incidences on February 1 might be caused by approximate-date records among some patients
 admitted to the centralized quarantine after February 2. The actual illness onset dates for these
 patients were likely to be between January 29 and February 1.

29 (S2) Assume an incubation period of 4.1 days (lower 95% CI from reference <sup>2</sup>) and presymptomatic

infectious period of 1.1 days (lower 95% CI from reference  $^{10}$  is 0.8 days, but our discrete stochastic

1

| 2  | model requires $D_p > 1$ ), equivalent to set $D_e = 3$ and $D_p = 1.1$ , and adjust $P(0)$ and $E(0)$            |
|----|---|
| 3  | accordingly.  |
| 4  | (S3) Assume an incubation period of 7 days (upper 95% CI from reference <sup>2</sup> ) and presymptomatic         |
| 5  | infectious period of 3 days (upper 95% CI from reference <sup>10</sup> ), equivalent to set $D_e = 4$ and $D_p =$ |
| 6  | 3, and adjust $P(0)$ and $E(0)$ accordingly.  |
| 7  | (S4) Assume the transmissibility of the presymptomatic and unascertained cases is $\alpha = 0.46$ (lower 95%)     |
| 8  | CI from reference <sup>15</sup> ) of the ascertained cases.   |
| 9  | (S5) Assume the transmissibility of the presymptomatic and unascertained cases is $\alpha = 0.62$ (upper 95%)     |
| 10 | CI from reference <sup>15</sup> ) of the ascertained cases.   |
| 11 | (S6) Assume the initial ascertainment rate is $r_0 = 0.14$ (lower 95% CI of the estimate using Singapore          |
| 12 | data) and adjust $A(0)$ , $P(0)$ , and $E(0)$ accordingly.  |
| 13 | (87) Assume the initial ascertainment rate is $r_0 = 0.42$ (upper 95% CI of the estimate using Singapore          |
| 14 | data) and adjust $A(0)$ , $P(0)$ , and $E(0)$ accordingly.  |
| 15 | (S8) Assume the initial ascertainment rate is $r_0 = 1$ (theoretical upper limit) and adjust $A(0)$ , $P(0)$ ,    |
| 16 | and $E(0)$ accordingly.   |
| 17 | (S9) Assume no unascertained cases by fixing $r_0 = r_{12} = r_3 = r_4 = r_5 = 1$ . We test if the full model is  |
| 18 | significantly better than this simplified model using likelihood ratio test.                                      |
|    |   |

| Case ID | Arrival date | Symptom onset | Confirmed date |
|---------|--------------|---------------|----------------|
| 1       | 2020/1/20    | 2020/1/21     | 2020/1/23      |
| 2       | 2020/1/21    | 2020/1/21     | 2020/1/24      |
| 3       | 2020/1/20    | 2020/1/23     | 2020/1/24      |
| 4       | 2020/1/22    | 2020/1/23     | 2020/1/25      |
| 5       | 2020/1/18    | 2020/1/24     | 2020/1/27      |
| 6       | 2020/1/19    | 2020/1/25     | 2020/1/27      |
| 7       | 2020/1/23    | 2020/1/24     | 2020/1/27      |
| 8       | 2020/1/19    | 2020/1/24     | 2020/1/28      |
| 9       | 2020/1/19    | 2020/1/24     | 2020/1/29      |
| 10      | 2020/1/20    | 2020/1/21     | 2020/1/29      |
| 11      | 2020/1/22    | 2020/1/27     | 2020/1/29      |
| 12      | 2020/1/22    | 2020/1/26     | 2020/1/29      |
| 13      | 2020/1/21    | 2020/1/28     | 2020/1/30      |
| 16      | 2020/1/22    | 2020/1/23     | 2020/1/31      |
| 18      | 2020/1/22    | 2020/1/30     | 2020/2/1       |
| 26      | 2020/1/21    | 2020/1/28     | 2020/2/4       |

Extended Data Table 1. COVID-19 cases exported from Wuhan to Singapore before January 23, 2020.

Source: https://co.vid19.sg/singapore/dashboard

| Parameter      | Meaning  | Jan 1-9                | Jan 10-22              | Jan 23-Feb 1 | Feb 2-16   | Feb 17-Mar 8 |
|----------------|--|------------------------|------------------------|--------------|------------|--------------|
| b              | Transmission rate of ascertained cases   | <i>b</i> <sub>12</sub> | <i>b</i> <sub>12</sub> | $b_3$        | $b_4$      | $b_5$        |
| r              | Ascertainment rate   | $r_{12}$               | <i>r</i> <sub>12</sub> | $r_3$        | $r_4$      | $r_5$        |
| α              | Ratio of transmission rate for presymptomatic and unascertained over ascertained cases | 0.55                   | 0.55                   | 0.55         | 0.55       | 0.55         |
| D <sub>e</sub> | Latent period  | 2.9                    | 2.9                    | 2.9          | 2.9        | 2.9          |
| $D_p$          | Presymptomatic infectious period   | 2.3                    | 2.3                    | 2.3          | 2.3        | 2.3          |
| $D_i$          | Symptomatic infectious period  | 2.9                    | 2.9                    | 2.9          | 2.9        | 2.9          |
| $D_q$          | Duration from illness onset to isolation   | 21                     | 15                     | 10           | 6          | 2            |
| $D_h$          | Isolation period   | 30                     | 30                     | 30           | 30         | 30           |
| Ν              | Population size  | 10,000,000             | 10,000,000             | 10,000,000   | 10,000,000 | 10,000,000   |
| n              | Daily inbound and outbound size  | 500,000                | 800,000                | 0            | 0          | 0            |

Extended Data Table 2. Parameter settings for five periods in the main analysis.

| Variable     | Meaning                           | Value     | Note  |
|--------------|-----------------------------------|-----------|---|
| <i>S</i> (0) | Number of susceptible individuals | 9,999,021 | S = N - E - P - A - I - H - R   |
| E(0)         | Number of exposed cases           | 478       | $E(0) = r_0^{-1}E_I(0)$ , where $E_I(0)$ was the number of ascertained cases<br>with onset during Jan 3-5, 2020 (day $(D_p + 1)$ to day $(D_p + D_e)$ ) * |
| <i>P</i> (0) | Number of presymptomatic cases    | 326       | $P(0) = r_0^{-1} P_I(0)$ , where $P_I(0)$ was the number of ascertained cases<br>with onset during Jan 1-2, 2020 (day 1 to day $D_p$ ) *                  |
| <i>I</i> (0) | Number of ascertained cases       | 34        | Number of ascertained cases with onset during Dec 29-31, 2019 ( $D_i$ days before day 1)  |
| <i>A</i> (0) | Number of unascertained cases     | 114       | $A(0) = r_0^{-1}(1 - r_0)I(0) *$  |
| H(0)         | Number of isolated cases          | 27        | Number of cases reported by Dec 31, 2019  |
| R(0)         | Number of removed individuals     | 0         | Number of cases recovered by Dec 31, 2019   |

Extended Data Table 3. Initial state of the model for the main analysis.

\* The initial ascertainment rate  $r_0$  was assumed to be 0.23 in the main analysis. Day 1 was January 1, 2020.

| Extended Data | Table 4. | Estimated | ascertainment | rates from | the main | and sensit | tivity ana | alyses. |
|---------------|----------|-----------|---------------|------------|----------|------------|------------|---------|
|               |          |           |               |            |          |            | •          |         |

| Analysis | $r_{12}$         | $r_3$            | $r_4$            | $r_5$            | Overall          |
|----------|------------------|------------------|------------------|------------------|------------------|
| Main     | 0.15 (0.13-0.17) | 0.14 (0.12-0.17) | 0.10 (0.08-0.12) | 0.16 (0.13-0.21) | 0.13 (0.11-0.16) |
| S1       | 0.15 (0.12-0.17) | 0.15 (0.12-0.18) | 0.11 (0.09-0.14) | 0.18 (0.14-0.24) | 0.14 (0.11-0.17) |
| S2       | 0.14 (0.12-0.17) | 0.15 (0.12-0.18) | 0.11 (0.08-0.13) | 0.17 (0.13-0.22) | 0.14 (0.11-0.17) |
| S3       | 0.14 (0.12-0.16) | 0.13 (0.10-0.16) | 0.09 (0.07-0.11) | 0.16 (0.12-0.20) | 0.12 (0.10-0.15) |
| S4       | 0.15 (0.12-0.17) | 0.14 (0.11-0.17) | 0.10 (0.08-0.12) | 0.16 (0.12-0.21) | 0.13 (0.11-0.16) |
| S5       | 0.15 (0.13-0.17) | 0.14 (0.11-0.17) | 0.10 (0.08-0.12) | 0.16 (0.13-0.21) | 0.13 (0.11-0.16) |
| S6       | 0.09 (0.08-0.10) | 0.09 (0.07-0.10) | 0.06 (0.05-0.08) | 0.10 (0.08-0.13) | 0.08 (0.07-0.10) |
| S7       | 0.26 (0.22-0.30) | 0.25 (0.20-0.30) | 0.17 (0.14-0.22) | 0.29 (0.22-0.38) | 0.23 (0.19-0.28) |
| S8       | 0.54 (0.47-0.62) | 0.50 (0.41-0.59) | 0.35 (0.28-0.43) | 0.58 (0.45-0.73) | 0.47 (0.38-0.57) |

The estimates were displayed as mean (95% CrI) based on 10,000 MCMC samples.

| <b>Extended Data</b> | Table 5. 1 | Estimated | transmission | rates from | the main | and sensitivity | y analyses. |
|----------------------|------------|-----------|--------------|------------|----------|-----------------|-------------|
|                      |            |           |              |            |          | -               | -           |

| Analysis   | <b>b</b> <sub>12</sub> | <b>b</b> <sub>3</sub> | <i>b</i> <sub>4</sub> | <b>b</b> <sub>5</sub> |
|------------|------------------------|-----------------------|-----------------------|-----------------------|
| Main       | 1.31 (1.25-1.37)       | 0.40 (0.38-0.42)      | 0.17 (0.16-0.19)      | 0.10 (0.08-0.12)      |
| S1         | 1.31 (1.25-1.38)       | 0.37 (0.34 0.39)      | 0.17 (0.16-0.18)      | 0.10 (0.08-0.12)      |
| S2         | 1.50 (1.43-1.58)       | 0.53 (0.51-0.56)      | 0.25 (0.24-0.27)      | 0.15 (0.13-0.18)      |
| S3         | 1.46 (1.39-1.54)       | 0.34 (0.31-0.36)      | 0.11 (0.10-0.13)      | 0.04 (0.03-0.06)      |
| S4         | 1.53 (1.46-1.61)       | 0.47 (0.44-0.50)      | 0.21 (0.19-0.22)      | 0.12 (0.1-0.14)       |
| S5         | 1.18 (1.13-1.23)       | 0.36 (0.34-0.38)      | 0.16 (0.15-0.17)      | 0.09 (0.07-0.10)      |
| S6         | 1.34 (1.28-1.40)       | 0.41 (0.38-0.44)      | 0.18 (0.17-0.19)      | 0.10 (0.08-0.12)      |
| <b>S</b> 7 | 1.27 (1.21-1.34)       | 0.39 (0.36-0.41)      | 0.17 (0.16-0.18)      | 0.10 (0.08-0.12)      |
| <b>S</b> 8 | 1.20 (1.14-1.27)       | 0.36 (0.34-0.39)      | 0.17 (0.16-0.18)      | 0.10 (0.09-0.12)      |
| S9         | 0.93 (0.92-0.94)       | 0.26 (0.25-0.27)      | 0.17 (0.16-0.17)      | 0.18 (0.16-0.20)      |

The estimates were displayed as mean (95% CrI) based on 10,000 MCMC samples.

| Analysis   | Jan 1-9          | Jan 10-22        | Jan 23-Feb 1     | Feb 2-16         | Feb 17-Mar 8      |
|------------|------------------|------------------|------------------|------------------|-------------------|
| Main       | 3.54 (3.41-3.66) | 3.32 (3.20-3.44) | 1.18 (1.11-1.25) | 0.51 (0.47-0.54) | 0.27 (0.23-0.32)  |
| <b>S</b> 1 | 3.54 (3.41-3.69) | 3.32 (3.20-3.46) | 1.09 (1.02-1.16) | 0.51 (0.47-0.54) | 0.27 (0.23-0.32)  |
| S2         | 3.21 (3.09-3.32) | 3.03 (2.92-3.13) | 1.23 (1.16-1.29) | 0.57 (0.54-0.60) | 0.33 (0.28-0.37)  |
| S3         | 4.37 (4.19-4.56) | 4.07 (3.91-4.25) | 1.12 (1.03-1.21) | 0.38 (0.34-0.42) | 0.14 (0.08-0.20)  |
| S4         | 3.56 (3.43-3.69) | 3.34 (3.22-3.46) | 1.18 (1.11-1.25) | 0.51 (0.48-0.54) | 0.27 (0.23-0.32)  |
| S5         | 3.53 (3.39-3.66) | 3.31 (3.18-3.44) | 1.18 (1.11-1.26) | 0.51 (0.47-0.54) | 0.27 (0.23-0.32)  |
| <b>S</b> 6 | 3.52 (3.39-3.65) | 3.29 (3.17-3.42) | 1.19 (1.12-1.27) | 0.51 (0.48-0.55) | 0.28 (0.23-0.33)  |
| <b>S</b> 7 | 3.60 (3.46-3.74) | 3.38 (3.26-3.51) | 1.17 (1.10-1.24) | 0.50 (0.47-0.53) | 0.27 (0.23-0.32)  |
| <b>S</b> 8 | 3.79 (3.68-3.91) | 3.58 (3.48-3.69) | 1.15 (1.09-1.22) | 0.50 (0.47-0.53) | 0.27 (0.23-0.32)  |
| S9         | 3.42 (3.40-3.45) | 3.25 (3.23-3.27) | 0.91 (0.88-0.95) | 0.53 (0.51-0.56) | 0.44 (0.39- 0.50) |

Extended Data Table 6. Estimated  $R_{\theta}$  for different periods from the main and sensitivity analyses.

The estimates were displayed as mean (95% CrI) based on 10,000 MCMC samples.

| Extended Data Table 7. Prediction of the end | ing date of COVID-19 | epidemic in Wuhan from | the main and sensitivity analyses. |
|--|----------------------|------------------------|------------------------------------|
|--|----------------------|------------------------|------------------------------------|

| Analysis   | First day of no ascertained infections | Clearance of all infections |
|------------|--|-----------------------------|
| Main       | Mar 25 (Mar 18 to Apr 2)               | Apr 21 (Apr 8 to May 11)    |
| S1         | Mar 25 (Mar 18 to Apr 1)               | Apr 20 (Apr 7 to May 11)    |
| S2         | Mar 26 (Mar 19 to Apr 2)               | Apr 22 (Apr 8 to May 13)    |
| <b>S</b> 3 | Mar 23 (Mar 16 to Mar 31)              | Apr 19 (Apr 6 to May 8)     |
| S4         | Mar 25 (Mar 18 to Apr 1)               | Apr 21 (Apr 8 to May 11)    |
| S5         | Mar 25 (Mar 18 to Apr 2)               | Apr 21 (Apr 8 to May 11)    |
| S6         | Mar 25 (Mar 18 to Apr 2)               | Apr 24 (Apr 11 to May 15)   |
| S7         | Mar 25 (Mar 18 to Apr 1)               | Apr 17 (Apr 3 to May 7)     |
| <b>S</b> 8 | Mar 24 (Mar 17 to Mar 31)              | Apr 10 (Mar 28 to Apr 29)   |
| S9         | Apr 2 (Mar 24 to Apr 13)               | Apr 19 (Apr 2 to May 15)    |

The estimates were displayed as mean date (95% CrI) based on 10,000 stochastic simulations with parameter values from MCMC sampling. First day of no ascertained infections means the first day of I = 0.

Clearance of all infections means the first day of E = P = A = I = 0.



**Extended Data Fig. 1. One simulated dataset with two periods.** We estimated  $b_1$ ,  $b_2$ ,  $r_1$ , and  $r_2$  when the other parameters were specified to their true values. (A) Daily incidences. (B) Number of active infectious cases per day, including both ascertained and unascertained cases. The shaded areas indicate 95% CrIs of the estimated values.



Extended Data Fig. 2. Parameter estimation on simulated epidemic curves with two periods. Each row represents an estimated parameter as indicated on the right, including  $(R_0)_1$ ,  $(R_0)_2$ ,  $r_1$ , and  $r_2$ . The grey dashed line in each row represents the true value of the parameter to be estimated. Each column represents a specified parameter as indicated on the top, including  $D_e$ ,  $D_p$ ,  $D_i$ ,  $D_q$ ,  $\alpha$ , and  $r_0$ , which we specified by the true values or 20% lower or higher than the true values. Each box represents estimates from 100 replicates.



**Extended Data Fig. 3. Trace plots of MCMC for the main analysis of real data.** Each panel represents the trajectory of 10,000 sampled values for a parameter indicated on the top of the panel. We generated three Markov chains with different initial values, which were colored by orange, red, and blue. The Gelman-Rubin diagnostic was 1.00, indicating convergence of MCMC.



**Extended Data Fig. 4. Sensitivity analysis by adjusting the daily incidences from January 29 to February 1 to their average (sensitivity analysis S1).** Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 2 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



**Extended Data Fig. 5. Sensitivity analysis assuming an incubation period of 4.1 days and a presymptomatic infectious period of 1.1 days (sensitivity analysis S2).** Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



**Extended Data Fig. 6. Sensitivity analysis assuming an incubation period of 7 days and a presymptomatic infectious period of 3 days (sensitivity analysis S3).** Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



**Extended Data Fig. 7. Sensitivity analysis assuming the transmissibility of the presymptomatic and unascertained cases is 0.46 of the ascertained cases (sensitivity analysis S4).** Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



**Extended Data Fig. 8. Sensitivity analysis assuming the transmissibility of the presymptomatic and unascertained cases is 0.62 of the ascertained cases (sensitivity analysis S5).** Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



Extended Data Fig. 9. Sensitivity analysis assuming the initial ascertainment rate is  $r_0 = 0.14$  (sensitivity analysis S6). Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



Extended Data Fig. 10. Sensitivity analysis assuming the initial ascertainment rate is  $r_0 = 0.42$  (sensitivity analysis S7). Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



Extended Data Fig. 11. Sensitivity analysis assuming the initial ascertainment rate is  $r_0 = 1$  (sensitivity analysis S8). Parameters were estimated by fitting data from January 1 to February 29. (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



Extended Data Fig. 12. Sensitivity analysis assuming complete ascertainment at any time (sensitivity analysis S9). Parameters were estimated by fitting data from January 1 to February 29. Compared to the full model, this simplified model fit the data significantly worse (likelihood ratio test,  $\chi_4^2 = 260$ , p = 0). (A) Prediction using parameters from period 5 (February 17-29). (B) Estimated R<sub>0</sub> for each period. The mean and 95% CrI (in parentheses) are labeled below or above the violin plots. (C) Prediction using parameters from period 4 (February 2-16). (D) Prediction using parameters from period 3 (January 23-February 1). (E) Prediction using parameters from period 2 (January 10-22). The shaded areas in (A, C, D and E) are 95% CrI. (F) Estimated number of active infectious cases in Wuhan from January 1 to March 8.



Extended Data Fig. 13. Estimation of  $R_0$  using daily incidence data starting from December 9. Following the main analysis, we assumed  $r_0 = 0.23$  and set I(0) = 1, A(0) = 3, E(0) = 17 and P(0) = H(0) = R(0) = 0 accordingly. We assumed transmission rate b, ascertainment rate r, and duration from illness onset to hospitalization  $D_q$  (set to 21 days) were the same until January 22, 2020. All the other settings were the same as in the main analysis. The shaded area in the plot indicates 95% CrIs estimated by the deterministic model with 10,000 sets of parameter values sampled from MCMC. Unlike other analyses, we did not construct 95% CrIs by stochastic simulations, because stochastic fluctuations at the early days would have extremely large impacts due to low counts, leading to unreasonable CrIs. The inserted histogram shows the distribution of the estimated  $R_0$  from December 9, 2019 to January 22, 2020, for which the mean estimate was 3.38 (95% CrI: 3.28-3.48).